CDC Guidelines for Pre-Exposure Prophylaxis to Prevent HIV Infection

Daily oral tenofovir/FTC coupled with risk-reduction services and careful monitoring is recommended as one prevention option for high-risk men who have sex with men, heterosexuals, and injection-drug users.

Sponsoring Organizations: CDC–U.S. Public Health Service

Target Population: Primary care clinicians, HIV/infectious diseases specialists, sexually transmitted disease clinics, public health officials

Background and Objective

Despite advances in HIV awareness and treatment, about 50,000 people in the U.S. become infected each year. Numerous clinical studies evaluating pre-exposure prophylaxis (PrEP) in high-risk men who have sex with men (MSM), heterosexuals, and injection-drug users (IDUs) have shown that consistent use of tenofovir/FTC significantly reduces the risk for HIV acquisition.

What's Changed

Previous CDC recommendations for use of PrEP, published as interim guidance (NEJM JW AIDS Clin Care Feb 14 2011 and Aug 30 2012) have been finali…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes